Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

JB-101

Phase 2Biologic

JJuntendo University

JB-101 is one of 10 biologic programs targeting Tolerance. It is currently in Phase 2.

1

Indications

1

Total Trials

1

Active Trials

9

Competitors

Pipeline

Status by Indication[3][1]

Indication

ToleranceActive, not recruiting

TolerancePhase 2

Active, not recruiting

Competition

Competitive Landscape

12 competitors in Tolerance

#DrugCompanyPhaseTrials

Rituxan

Fludara

Cytoxan

BBaxter Healthcare Corporation

Avigan

AAppili Therapeutics Inc.

Siplizumab

UUniversity of Alabama at Birmingham

Experimental

JB-101

JJuntendo University

Levo-Dromoran

VValeant Pharmaceuticals

Tazorac

FFougera Pharmaceuticals Inc.

Oxytocin Treatment

UUniversity of Electronic Science and Technology of China

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tolerance1 trial

Induction of Transplant Tolerance in LDLT Via iTS

Active, not recruiting·JJuntendo University·Phase 1/2·NCT04950842·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for JB-101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JB-101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JB-101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Juntendo University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: JJuntendo University

Related News